KalVista Pharmaceuticals, a leading clinical stage pharmaceutical company, presented compelling real-world data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, held in Valencia, Spain. The data, garnered from surveys of US patients with Hereditary Angioedema (HAE), assessed their experiences with injectable on-demand treatments.
The company addressed the persisting unmet needs in HAE, shedding light on why attacks sometimes go untreated. By gathering feedback directly from patients, KalVista Pharmaceuticals aimed to gain a deeper understanding of the reasons behind the underutilization of treatment options. This valuable information will be vital for developing more effective strategies and interventions.
In addition to the patient surveys, KalVista Pharmaceuticals announced the acceptance of multiple abstracts and a symposium at the EAACI Congress 2024. The presentations covered various topics related to HAE, including the Phase 3 KONFIDENT trial results for the use of oral Sebetralstat as an on-demand treatment. Notable researchers and experts in this field, such as Marc Riedl, Henriette Farkas, and Emel Aygren-Prsn, contributed to the discussions.
Furthermore, KalVista Pharmaceuticals emphasized its commitment to investor engagement by participating in fireside chats at upcoming conferences, including the Stifel 2024 Tailoring Genes: Genetic Medicines Forum. These interactions will offer the opportunity to discuss the latest advancements in genetic medicines and provide insights into the company’s strategic direction.
The impact of KalVista Pharmaceuticals’ contributions at EAACI Congress 2024 extends beyond just addressing the unmet needs in HAE. By presenting real-world data and trial results, the company not only demonstrates its dedication to advancing the understanding and management of this rare disease but also highlights its position as a key player in the pharmaceutical industry. Through ongoing collaboration and innovation, KalVista Pharmaceuticals aims to improve the lives of HAE patients and usher in a new era of effective treatments.
Comments